α-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies. - Wikidata - awgldk - TriplyDB

α-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies.

α-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies.

http://www.wikidata.org/entity/Q30471591

about

Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?A progressive mouse model of Parkinson's disease: the Thy1-aSyn ("Line 61") mice Characterization of cognitive deficits in rats overexpressing human alpha-synuclein in the ventral tegmental area and medial septum using recombinant adeno-associated viral vectors Impaired c-Fos and polo-like kinase 2 induction in the limbic system of fear-conditioned α-synuclein transgenic mice Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies.Identification of bilateral changes in TID1 expression in the 6-OHDA rat model of Parkinson's disease Glial A30P alpha-synuclein pathology segregates neurogenesis from anxiety-related behavior in conditional transgenic mice.Severely impaired hippocampal neurogenesis associates with an early serotonergic deficit in a BAC α-synuclein transgenic rat model of Parkinson's disease.Autonomic dysfunction and plasticity in micturition reflexes in human α-synuclein mice.Pathological α-synuclein impairs adult-born granule cell development and functional integration in the olfactory bulb.Late-onset dementia: a mosaic of prototypical pathologies modifiable by diet and lifestyle.Overexpression of the calpain-specific inhibitor calpastatin reduces human alpha-Synuclein processing, aggregation and synaptic impairment in [A30P]αSyn transgenic mice.Hippocampal proliferation is increased in presymptomatic Parkinson's disease and due to microglia.Development of targeted therapies for Parkinson's disease and related synucleinopathies Microglial phenotypes and toll-like receptor 2 in the substantia nigra and hippocampus of incidental Lewy body disease cases and Parkinson's disease patients.Spatial quality control bypasses cell-based limitations on proteostasis to promote prion curing.Cognition in movement disorders: where can we hope to be in ten years?Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease Α-synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration.The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson's disease.Animal models of the non-motor features of Parkinson's disease.Parkinson's disease and α-synuclein expression Complex Effects of the ZSCAN21 Transcription Factor on Transcriptional Regulation of α-Synuclein in Primary Neuronal Cultures and in Vivo Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations The Synucleinopathies: Twenty Years On.Enhanced ubiquitin-dependent degradation by Nedd4 protects against α-synuclein accumulation and toxicity in animal models of Parkinson's disease.Lysosome-dependent pathways as a unifying theme in Parkinson's disease.α-Synuclein and neuronal cell death.Mechanisms underlying synaptic vulnerability and degeneration in neurodegenerative disease.Synucleinopathies: common features and hippocampal manifestations.Hereditary spastic paraplegia-linked REEP1 modulates endoplasmic reticulum/mitochondria contacts.The ER retention protein RER1 promotes alpha-synuclein degradation via the proteasome.α-Synuclein inhibits intersynaptic vesicle mobility and maintains recycling-pool homeostasis.A progressive dopaminergic phenotype associated with neurotoxic conversion of α-synuclein in BAC-transgenic rats.Comparison of α-synuclein immunoreactivity in the hippocampus between the adult and aged beagle dogs.Overexpression of synphilin-1 promotes clearance of soluble and misfolded alpha-synuclein without restoring the motor phenotype in aged A30P transgenic mice.Spread of aggregates after olfactory bulb injection of α-synuclein fibrils is associated with early neuronal loss and is reduced long term.Critical appraisal of pathology transmission in the α-synuclein fibril model of Lewy body disorders.The Transcellular Propagation and Intracellular Trafficking of α-Synuclein.Tau oligomers mediate α-synuclein toxicity and can be targeted by immunotherapy.

P2860

Q26801733-ACC090A6-36E6-475E-8CE4-ACE8FB9ED0BF Q26859072-E5EBF8D8-79C7-4A7A-866D-7CFF9344A5CF Q27318127-EC2AE17F-D8E2-4FF8-8310-FF4BA78EA5EF Q27334377-C95ACA74-A962-44F3-8194-986270F63FA2 Q27686837-F5C395BE-3310-4E43-9C5C-881A2AEABB7D Q28477415-E283D16C-0DC2-4E6D-9829-3A0086C0BFB1 Q30620210-DBBA4046-1E1F-4879-97E1-BC2F025048EB Q30795299-90506B99-99ED-4A25-8CA7-D9CC0EBE8CA8 Q33640037-A24A646B-5106-4018-8E18-4C16DB0347B8 Q33729317-1D2249E8-75AA-476F-8139-C03EE47E1AB4 Q33817811-BE802C6A-2747-4E9F-9F73-51CFE7BB2B4D Q33947949-E4EE0E86-B8BD-4D44-B856-500EF9F1E3CF Q34100703-CB1788BB-EDA1-463F-8E64-40FE267EB513 Q34238616-FBB9BAB7-10B8-475C-8B97-BF7D2B7007A2 Q34470963-AB33C876-11D1-424A-878D-BF2666C4BFF3 Q34729587-A9FC8BE2-D86B-42B2-94DB-7B98C5AC01DA Q35211553-EB1BF800-A481-494F-A96B-5B21C7EB54B6 Q35442728-423BF3C8-A29D-4A60-80E9-487E00D8CB9F Q35542169-AB9050C4-CAFB-447B-9B08-6F2D722DC067 Q35894167-F61B11A0-73F1-46F9-B58B-848FE725507F Q36235578-EEE8E98D-840A-4FC3-9028-B3B69266CAA3 Q36346542-470A76ED-D1C5-445F-AF99-9CC6F28D0D10 Q36884715-AD13DA14-A9E7-468F-8ADD-04CF29030883 Q37566684-6E90CC0C-326E-41C5-B307-B7C0549213EB Q37693375-381ECC9B-5E78-45E7-9E63-9401A359D584 Q37706391-FB0B0276-89DD-4CCE-8AD9-F76F01518A30 Q38038561-70370A7F-BF63-4CA6-B3B5-7D5E032A4F56 Q38039369-4C28E30F-5179-46C5-80AF-89B6E5B12176 Q38071648-BDB25ABA-8582-4D26-8F31-FD0B0CD9F851 Q39003423-298E3128-68F5-4421-BA4F-8F4573215986 Q40707464-9BC456DA-6F59-4735-8783-68513864B462 Q41635176-1B8D8919-DC84-43B6-BFD8-95859C9755C8 Q41901772-0FD65022-A246-4B30-802D-F56CAEB6C8C3 Q43247253-C96E1382-FB80-43FE-AD43-1573B534B137 Q43483324-CBDBE1FF-9E1C-4182-AE6F-662B21738C27 Q43752239-16799F5F-D586-45E6-88B9-CC114EBCDBCC Q47361450-CA08D2EC-0DD9-4352-B3D6-2B1FF24CE26C Q47619917-1A589A79-496C-487C-8A88-7FFEF5E24104 Q51284194-5B8C22B3-0D78-43C2-9382-968F9A8B6C9F Q51762778-5DDDB773-ED62-4E30-AEB0-B44DEE7226D3

P2860

α-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies.

http://www.wikidata.org/entity/Q30471591

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

α-Syn suppression reverses syn ...... of dementia with Lewy bodies.

@ast

α-Syn suppression reverses syn ...... of dementia with Lewy bodies.

@en

type

label

α-Syn suppression reverses syn ...... of dementia with Lewy bodies.

@ast

α-Syn suppression reverses syn ...... of dementia with Lewy bodies.

@en

prefLabel

α-Syn suppression reverses syn ...... of dementia with Lewy bodies.

@ast

α-Syn suppression reverses syn ...... of dementia with Lewy bodies.

@en

P1433

Q30471591-66DFBEDE-8381-4652-AADC-6A8039AC13A1

P1476

Q30471591-C55DD746-323B-42E9-A945-0F956C7DDEA1

P2093

Q30471591-1007D176-1276-440F-910F-0DFF74DF6022

Q30471591-4E811B27-7D4B-49F7-8F35-8A64436B7BB5

Q30471591-56BAFE7B-F8A1-44D6-8DAF-AE337B6C9F4D

Q30471591-85CD891D-E2B2-4960-A746-268D9574D250

Q30471591-93BFA95C-BC20-434E-8704-F9C9146507B3

Q30471591-FD9232AC-A6F2-462C-B25D-6E1387BF2E40

P2860

Q30471591-0155F4DB-0410-4423-AF5B-CA72CD2BF823

Q30471591-049F94BB-0D1A-4B02-9CCA-4A4BB3933CCF

Q30471591-06484180-26E9-4ADC-B913-B5D340EE6870

Q30471591-11301210-CA57-45B0-B545-9C177CBFD31D

Q30471591-172A1FE8-8AC1-4B7F-8D45-B8FB8541F634

Q30471591-255993FD-43CE-4B9E-9194-F48A35668B03

Q30471591-35002316-1D17-43C5-9145-D9AB2924B6E0

Q30471591-4BBF0A0F-57CF-4FAF-9087-42D0AEFDBD30

Q30471591-4D1B4B2C-1BCF-44E2-AFFF-8FD22E9CBCBE

Q30471591-4D9E0433-9D94-4A03-B30E-D12FF4A44E66

P304

Q30471591-C89A2AE6-0E68-470E-A73B-017FE6D77BA1

P31

Q30471591-E44E8761-FFC3-4536-A016-14020E6319EC

P356

Q30471591-532982E9-DB61-41F9-A979-2F2111D0324B

P407

Q30471591-777B6667-FD60-4EF8-8B44-EB27FD8D1F5C

P433

Q30471591-D7DDB138-CC93-44C2-AED7-DF536D724890

P478

Q30471591-325B9677-F912-48F7-97CC-F5325E98C255

P50

Q30471591-E30823CB-2FB5-4E9A-917C-901A95DAA78C

P577

Q30471591-A6C032DF-58A6-4E71-BC81-8F7AC37D5430

P698

Q30471591-FE946841-C52E-40A9-A514-A32E559C180F

P921

Q30471591-6151F028-BCF2-411D-82FB-BF0C45952965

P932

Q30471591-5A40E229-9EAE-4583-B175-336ECCBDDFFB

P356

JNEUROSCI.0618-11.2011

P1433

Journal of Neuroscience

P1476

α-Syn suppression reverses syn ...... of dementia with Lewy bodies.

@en

P2093

Chi Li

http://www.w3.org/2001/XMLSchema#string

Edward B Lee

http://www.w3.org/2001/XMLSchema#string

James H Soper

http://www.w3.org/2001/XMLSchema#string

Victoria M Kehm

http://www.w3.org/2001/XMLSchema#string

Virginia M-Y Lee

http://www.w3.org/2001/XMLSchema#string

Youngshin Lim

http://www.w3.org/2001/XMLSchema#string

P2860

Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease

Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro

Genome-wide association study reveals genetic risk underlying Parkinson's disease

Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models

Alpha-synuclein in Lewy bodies

C. elegans model identifies genetic modifiers of alpha-synuclein inclusion formation during aging

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium

Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease

Tau suppression in a neurodegenerative mouse model improves memory function

Modality-specific retrograde amnesia of fear

P304

10076-10087

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1523/JNEUROSCI.0618-11.2011

http://www.w3.org/2001/XMLSchema#string

P407

P433

27

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

John Q. Trojanowski

P577

2011-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21734300

http://www.w3.org/2001/XMLSchema#string

P921

P932

3144489

http://www.w3.org/2001/XMLSchema#string